Cognition Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.
Our lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. We have initially focused on the development of CT1812 for the treatment of Alzheimer’s disease, or AD, a disease that afflicts approximately 6.2 million people in the United States and disease prevalence is expected to more than double by 2050. CT1812 is the first S2R antagonist to reach clinical trials and is currently in Phase 2 development for the treatment of mild to moderate Alzheimer’s disease (AD).
Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date we have been awarded approximately $168.4 million in grants and financial support primarily from the National Institute of Aging, or NIA, a division of the National Institutes of Health to support our clinical trials.
(Note: Cognition Therapeutics upsized its IPO at pricing on Oct. 7, 2021, to 3.77 million shares, up from 3.35 million in the prospectus, and priced the stock at $12 – the mid-point of its $11-to-$13 range – to raise $45.24 million.)
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||2500 Westchester Ave., Purchase, NY 10577, US|
|Phone Number||(412) 481-2210|
|View Prospectus:||Cognition Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-9.5 mil (last 12 months)|
|Price range||$12.00 - $12.00|
|Est. $ Volume||$45.2 mil|
|Manager / Joint Managers||B. Riley, Inc./ Oppenheimer & Co.|
|Expected To Trade:||10/8/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|